In Brief: Biosite Diagnostics Triage
This article was originally published in The Gray Sheet
Biosite Diagnostics Triage: Point-of-care cardiac test panel for rapid diagnosis of heart attacks gains additional 510(k) clearances for quality control, calibration verification and Triage meter components, clearing the way for a product launch in early spring pending completion of internal validation of the manufacturing process, the firm says. San Diego-based Biosite had gained clearance for CK-MB, myoglobin and troponin I measurement in October ("The Gray Sheet" Oct. 20, In Brief), but was awaiting the additional clearances prior to marketing. The Triage meter is used in tandem with the panel to quantitatively measure levels of the target analytes...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.